Qiagen N.V. (NYSE:QGEN) Given Average Rating of "Hold" by Analysts

Shares of Qiagen N.V. (NYSE:QGEN - Get Free Report) have been assigned a consensus rating of "Hold" from the fourteen brokerages that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, eight have given a hold recommendation, four have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $42.4250.

QGEN has been the topic of a number of research analyst reports. Robert W. Baird set a $43.00 target price on Qiagen and gave the company an "outperform" rating in a report on Wednesday, April 29th. TD Cowen reissued a "hold" rating on shares of Qiagen in a report on Wednesday, July 15th. Morgan Stanley upgraded Qiagen from an "overweight" rating to an "overweight" rating and upped their price objective for the stock from $40.00 to $42.00 in a research report on Tuesday, June 23rd. Stifel Nicolaus set a $36.00 price objective on Qiagen and gave the company a "hold" rating in a research note on Monday, May 18th. Finally, Jefferies Financial Group reiterated a "buy" rating and issued a $48.00 target price on shares of Qiagen in a research report on Thursday.

Qiagen Price Performance

QGEN stock opened at $41.71 on Friday. The company's 50-day moving average price is $39.32 and its two-hundred day moving average price is $41.69. The firm has a market cap of $8.59 billion, a P/E ratio of 21.37, a P/E/G ratio of 4.19 and a beta of 0.63. The company has a quick ratio of 2.57, a current ratio of 3.21 and a debt-to-equity ratio of 0.49. Qiagen has a 12 month low of $32.53 and a 12 month high of $57.81.

Qiagen (NYSE:QGEN - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $0.62 earnings per share for the quarter, topping analysts' consensus estimates of $0.60 by $0.02. The company had revenue of $535.00 million during the quarter, compared to the consensus estimate of $527.50 million. Qiagen had a net margin of 19.49% and a return on equity of 14.24%. The firm's quarterly revenue was up .2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.60 EPS. Qiagen has set its FY 2026 guidance at 2.430- EPS. On average, analysts anticipate that Qiagen will post 2.43 earnings per share for the current fiscal year.

Qiagen Increases Dividend

The business also recently declared an annual dividend, which was paid on Tuesday, July 14th. Investors of record on Tuesday, July 7th were issued a dividend of $0.35 per share. This is a boost from Qiagen's previous annual dividend of $0.26. The ex-dividend date of this dividend was Tuesday, July 7th. This represents a dividend yield of 90.0%. Qiagen's payout ratio is presently 18.32%.

Hedge Funds Weigh In On Qiagen

A number of institutional investors have recently added to or reduced their stakes in the stock. Canvas Wealth Advisors LLC lifted its stake in Qiagen by 90.2% in the 2nd quarter. Canvas Wealth Advisors LLC now owns 30,119 shares of the company's stock valued at $1,178,000 after purchasing an additional 14,281 shares during the last quarter. Handelsbanken Fonder AB acquired a new position in shares of Qiagen during the second quarter worth $2,909,000. GAMMA Investing LLC lifted its stake in shares of Qiagen by 70.4% in the 2nd quarter. GAMMA Investing LLC now owns 3,521 shares of the company's stock valued at $138,000 after acquiring an additional 1,455 shares during the last quarter. Hilltop National Bank bought a new position in shares of Qiagen in the 2nd quarter valued at $50,000. Finally, Groupama Asset Managment acquired a new stake in shares of Qiagen during the 1st quarter valued at $500,000. 70.00% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Qiagen

Here are the key news stories impacting Qiagen this week:

• Positive Sentiment: Qiagen reported second-quarter adjusted EPS of $0.62, above the $0.60 consensus estimate, while revenue of $535 million exceeded expectations of $527.5 million. Revenue was broadly unchanged year over year, but the company said its growth pillars delivered 5% growth at constant exchange rates and that sales exceeded its prior outlook for a decline. QIAGEN Exceeds Q2 2026 Outlook as Pillars Deliver Solid Sales Growth; Reaffirms Full-Year Outlook
• Positive Sentiment: The company reaffirmed its full-year 2026 EPS outlook of approximately $2.43, in line with analyst expectations, while maintaining high profitability. Qiagen Earnings Conference Call
• Neutral Sentiment: Management’s second-quarter earnings call and presentation provided additional detail on the performance of Qiagen’s growth pillars and the company’s outlook, but did not materially change the full-year EPS forecast. Qiagen N.V. Q2 2026 Earnings Call Transcript
• Negative Sentiment: Third-quarter guidance was below consensus: EPS of $0.62 versus $0.63 expected and revenue of $538.3 million to $543.7 million versus $552.7 million expected. The revenue shortfall indicates analysts may need to reduce near-term estimates.
• Negative Sentiment: Although full-year EPS guidance matched consensus, full-year revenue guidance of roughly $2.1 billion was below the approximately $2.2 billion analyst estimate, tempering the impact of the quarterly beat.

About Qiagen

Qiagen NV NYSE: QGEN is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company's solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company's product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source